Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUOPANC phase II fluorescence imaging feasibility trial
NL-OMON54735Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2022
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cRGD-ZW800-1 in pancreatic cancer (PC) and cholangiocarcinoma (CCA), sponsored by Leiden University Medical Center. Primary endpoint: Visualization of the primary tumor. Started Nov 2022; status: completed.
02
Drugs
cRGD-ZW800-1
03
Conditions
pancreatic cancer (PC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NL-OMON54735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54735.